Metalloproteinases: their role in arthritis and potential as therapeutic targets

Bibliography

• PROCKOP DJ: What holds us together? Why do some of us fall apart? What can we do about it? Matrix Biol. (1998) 16:519–528.
   Google Scholar
• HARDINGHAM TE, FOSANG AJ: Proteoglycans: many forms and many functions. FASEB J. (1992) 6:861–870.
   PubMed Web of Science ®Google Scholar
• EIKENBERRY EF, BRUCKNER P: Supramolecular structure of cartilage matrix. In: Dynamics of cartilage and bone metabolism. Seibel MJ, Robins SP, Bilezikian JP (Eds), Academic Press, San Diego. USA (1999):289–300.
   Google Scholar
• STOOP R, VAN DER KRAAN PM, BUMA P, HOLLANDER AP, POOLE AR, VAN DEN BERG WB: Denaturation of Type II collagen in articular cartilage in experimental murine arthritis. Evidence for collagen degradation in both reversible and irreversible cartilage damage. J. Pathol (1999) 188:329–337.
   Google Scholar
• SHINGLETON WD, HODGES DJ, BRICK P, CAWSTON TE: Collagenase: a key enzyme in collagen turnover. Biochem. Cell Biol. (1996) 74:759–775.
   PubMed Web of Science ®Google Scholar
• BRINCKERHOFF CE, MATRISIAN LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev MM. Cell Biol. (2002) 3:207–214.
   PubMed Web of Science ®Google Scholar
• •A good historical overview of the MMP field.
   Google Scholar
• MURPHY G, KNAUPER V, ATKINSON S et al: Matrix metalloproteinases in arthritic disease. Arthritic Res. (2002) 4\(Suppl. 3):S39–S49.
   Google Scholar
• EGEBLAD M, WERB Z: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev Cancer(2002) 2:161–174.
   PubMed Web of Science ®Google Scholar
• •Excellent review of more subtle functions for MMPs.
   Google Scholar
• KONTTINEN YT, CEPONIS A, TAKAGI M et al.: New collagenolytic enzymes/cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: destruction from above. Matrix Biol. (1998) 17:585–601.
   PubMed Web of Science ®Google Scholar
• OHUCHI E, IMAI K, FUJII Y, SATO H, SEIKI M, OKADA Y: Membrane Type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. Biol. Chem. (1997) 272:2446–2451.
   Web of Science ®Google Scholar
• D'ORTHO M-P, WILL H, ATKINSON S et al: Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Ear. Biochem. (1997) 250:751–757.
   PubMedGoogle Scholar
• BILLINGHURST RC, DAHLBERG L, IONESCU M et al: Enhanced cleavage of Type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. (1997) 99:1534–1545.
   PubMed Web of Science ®Google Scholar
• LINDY 0, KONTTINEN YT, SORSA T et al.: Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritic Rheum. (1997) 40:1391–1399.
   Google Scholar
• TETLOW LC, WOOLLEY DE: Comparative immunolocalization studies of collagenase 1 and collagenase 3 production in the rheumatoid lesion, and by human chondrocytes and synoviocytes M vitro. Br. J. Rheumatol (1998) 37:64–70.
   PubMedGoogle Scholar
• KNAUPER V, LOPEZ-OTIN C, SMITH B, KNIGHT G, MURPHY G: Biochemical characterisation of human collagenase-3. Biol. Chem. (1996) 271:1544–1550.
   Web of Science ®Google Scholar
• NEUHOLD LA, KILLAR L, ZHAO W et al: Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J. Clin. Invest. (2001) 107:35–44.
   PubMed Web of Science ®Google Scholar
• ••Novel mouse model of OA using cartilage-specific overexpression of MMP-13.
   Google Scholar
• DAHLBERG L, BILLINGHURST RC, MANNER P et al.: Selective enhancement of collagenase-mediated cleavage of resident Type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum. (2000) 43:673–682.
   PubMed Web of Science ®Google Scholar
• •Some evidence that IVEVIP-1 is not important in OA (see also [1071).
   Google Scholar
• BALBIN M, FUEYO A, KNAUPER V et al: Identification and enzymatic characterisation of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. Biol. Chem. (2001) 276:10253–10262.
   Web of Science ®Google Scholar
• COLE AA, CHUBINSKAYA S, SCHUMACHER B et al: Chondrocyte matrix metalloproteinase-8 - human articular chondrocytes express neutrophil collagenase. Biol. Chem. (1996) 271:11023–11026.
   Web of Science ®Google Scholar
• HANEMAAIJER R, SORSA T, KONTTINEN YT et al.: Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells - regulation by tumor necrosis factor-a and doxycycline. J. Biol. Chem. (1997) 272:31504–31509.
   PubMed Web of Science ®Google Scholar
• KONTTINEN YT, AINOLA M, VALLEALA H et al.: Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58:691–697.
   PubMed Web of Science ®Google Scholar
• TETLOW LC, ADLAM DJ, WOOLLEY DE: Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. (2001) 44:585–594.
   PubMed Web of Science ®Google Scholar
• PETROW PK, WERNICKE D, SCHULZE WESTHOFF C et al.: Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane Type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61:391–397.
   Google Scholar
• TOMITA T, NAKASE T, KANEKO M et al.: Expression of extracellular matrix metalloproteinase inducer and enhancement of the production of matrix metalloproteinases in rheumatoid arthritis. Arthritic Rheum. (2002) 46:373–378.
   PubMedGoogle Scholar
• PRICE JS, CHAMBERS MG, POOLE AR, FRADIN A, MASON RM: Comparison of collagenase-cleaved articular cartilage collagen in mice in the naturally occurring STR/ort model of osteoarthritis and in collagen-induced arthritis. Osteoarthritis Cartilage (2002) 10:172–179.
   PubMed Web of Science ®Google Scholar
• HOLMBECK K, BIANCO P, CATERINA J et al.: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell (1999) 99:81–92.
   PubMed Web of Science ®Google Scholar
• ••Connective tissue phenotype of MT1-MMPknockout mouse.
   Google Scholar
• ZHOU Z, APTE SS, SOININEN R et al.: Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase 1. Proc. Nati Acad. Sci. USA (2000) 97:4052–4057.
   PubMed Web of Science ®Google Scholar
• ITOH T, IKEDA T, GOMI H, NAKAO S, SUZUKI T, ITOHARA S: Unaltered secretion of P-amyloid precursor protein in gelatinase a (matrix metalloproteinase 2)-deficient mice. Biol. Chem. (1997) 272:22389–22392.
   Web of Science ®Google Scholar
• MILNER JM, ELLIOT S-F, CAWSTON TE: Activation of procollagenases is a key point in cartilage collagen degradation. Arthritis Rheum. (2001) 44:2084–2096.
   PubMedGoogle Scholar
• •Highlighting the key role of enzyme activation in cartilage destruction (see also [30–32]).
   Google Scholar
• VAN LENT PL, HOLTHUYSEN AE, SLOETJES A, LUBBERTS E, VAN DEN BERG WB: Local overexpression of adenoviral IL-4 protects cartilage from metalloproteinase-induced destruction during immune complex-mediated arthritis by preventing activation of pro-MMPs. Osteoarthritis Cartilage (2002) 10:234–243.
   PubMed Web of Science ®Google Scholar
• VAN MEURS J, VAN LENT P, STOOP R et al.: Cleavage of aggrecan at the ASN341-PHE342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis. Arthritic Rheum. (1999) 42:2074–2084.
   PubMedGoogle Scholar
• VAN MEURS J, VAN LENT P, HOLTHUYSEN A et al: Active matrix metalloproteinases are present in cartilage during immune complex-mediated arthritis: a pivotal role for stromelysin-1 in cartilage destruction. J. Irninanol. (1999) 163:5633–5639.
   PubMed Web of Science ®Google Scholar
• CONSTANTIN A, LAUWERS- CANCES V, NAVAUX F et al.: Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study. Arthritic Rheum. (2002) 46:1754–1762.
   PubMed Web of Science ®Google Scholar
• CONSTANTIN A, LAUWERS-CANCES V, NAVAUX F et al: Collagenase-1 (MMP-1) and HLA-DRB1 gene polymorphisms in rheumatoid arthritis: a prospective longitudinal study. Rheurnatol. (2002) 29:15–20.
   PubMed Web of Science ®Google Scholar
• MOSS ML, WHITE JM, LAMBERT JH, ANDREWS RC: TACE and other ADAM proteases as targets for drug discovery. Drug Discov. Today (2001) 6:417–426.
   PubMed Web of Science ®Google Scholar
• NARDI JB, MARTOS R, WALDEN KKO, LAMPE DJ, ROBERTSON HM: Expression of lacunin, a large multidomain extracellular matrix protein, accompanies morphogenesis of epithelial monolayers in Man duca sexta. Insect Biochem. Mol. Biol. (1999) 29:883–897.
   PubMed Web of Science ®Google Scholar
• CAL S, OBAYA AJ, LLAMAZARES M, GARABAYA C, QUESADA V, LOPEZ- OTIN C: Cloning, expression analysis and structural characterisation of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene (2002) 283(1-2):49–62.
   PubMed Web of Science ®Google Scholar
• ••Novel ADAMTSs from genomic analysis,and review of ADAMTS family based on primary sequence and expression data.
   Google Scholar
• BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 385:729–733.
   PubMed Web of Science ®Google Scholar
• PESCHON JJ, SLACK JL, REDDY Petal.: An essential role for ectodomain shedding in mammalian development. Science (1998) 282:1281–1284.
   Google Scholar
• •Characterisation of TACE knockout.
   Google Scholar
• BLACK RA: Tumor necrosis factor-a converting enzyme. Int. J. Biochem. Cell Biol. (2002) 34:1–5.
   PubMed Web of Science ®Google Scholar
• MOHAN MJ, SEATON T, MITCHELL J et al.: The tumor necrosis factor-a converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry (2002) 41:9462–9469.
   PubMed Web of Science ®Google Scholar
• OHTA S, HARIGAI M, TANAKA M et al.: Tumour necrosis factor-a (TNF-a) converting enzyme contributes to production of TNF-a in synovial tissues from patients with rheumatoid arthritis. Rheumatol. (2001) 28(8):1756–1763.
   Web of Science ®Google Scholar
• PATEL IR, ATTUR MG, PATEL RN et al.: TNF-alpha convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-a. kninanol. (1998) 160(9):4570–4579.
   Google Scholar
• AMIN AR: Regulation of tumour necrosis factor-a and tumour necrosis factor-converting enzyme in human osteoarthritis. Osteoarthritis Cartilage (1999) 7(4):392–394.
   PubMed Web of Science ®Google Scholar
• BOHM BB, AIGNER T, GEHRSITZ A, BLOBEL CP, KALDEN JR, BURKHARDT H: Up regulation of MD C15 (metargidin) messenger RNA in human osteoarthritic cartilage. Arthritic Rheum. (1999) 42(9):1946–1950.
   PubMedGoogle Scholar
• CHUBINSKAYA S, CS-SZABO G, KUETTNER KE: ADAM-10 message is expressed in human articular cartilage. Histochem. Cytochem. (1998) 46(6):723–729.
   PubMed Web of Science ®Google Scholar
• CHUBINSKAYA S, MIKHAIL R, DEUTSCH A, TINDAL MH: ADAM-10 protein is present in human articular cartilage primarily in the membrane-bound form and is upregulated in response to IL-la in bovine nasal cartilage. J. Histochem. Cytochein. (2001) 49(9):1165–1176.
   PubMed Web of Science ®Google Scholar
• MCKIE N, EDWARDS T, DALLAS DJ et al.: Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes. Biochem. Biophys. Res. Commun. (1997) 230(2):235–239.
   Web of Science ®Google Scholar
• FLANNERY CR, LITTLE CB, CATERSON B, HUGHES CE: Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (MMPs) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes. Matrix Biol. (1999) 18(3):225–237.
   PubMed Web of Science ®Google Scholar
• SANDY JD, FLANNERY CR, NEAME PJ,LOHMANDER LS: The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the G1u373 - A1a374 bond of the interglobular domain. Clin. Invest. (1992) 89:1512–1516.
   Google Scholar
• •Early evidence for a 'specific' aggrecanase enzyme.
   Google Scholar
• LARK MW, BAYNE EK, FLANAGAN J et al: Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic and rheumatoid joints. Clin. Invest. (1997) 100(1):93–106.
   Google Scholar
• SINGER II, SCOTT S, KAWKA DW et al:Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis. Osteoarthritis Cartilage (1997) 5:407–418.
   PubMed Web of Science ®Google Scholar
• VAN MEURS JB, VAN LENT PL, HOLTHUYSEN AE, SINGER II, BAYNE EK, VAN DEN BERG WB: Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum. (1999) 42(6):1128–1139.
   PubMedGoogle Scholar
• FOSANG AJ, LAST K, MACIEWICZ R: Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. Clin. Invest. (1996) 98(10):2292–2299.
   Google Scholar
• TORTORELLA MD, BURN TC, PRATTA MA et al: Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science (1999) 284(5420):1664–1666.
   PubMed Web of Science ®Google Scholar
• ••Describes the cloning of the first`aggrecanase', assigning it to the ADAMTS family.
   Google Scholar
• ABBASZADE I, LIU RQ, YANG F et al.: Cloning and characterisation of ADAMTS11, an aggrecanase from the ADAMTS family. j. Biol. Chem. (1999) 274(33):23443–23450.
   PubMed Web of Science ®Google Scholar
• •Describes cloning of a second aggrecanase, expanding the potential therapeutic targets.
   Google Scholar
• KUNO K, OKADA Y, KAWASHIMA H, NAKAMURA H et al.: ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett. (2000) 478:241–245.
   PubMed Web of Science ®Google Scholar
• CARLOS RODROGUEZ-MANZANEQUE J, WESTLING J, THAI SN et al: ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem. Biophys. Res. Commun. (2002) 293(1):501–508.
   PubMed Web of Science ®Google Scholar
• ARNER EC, HUGHES CE, DECICO CP, CATERSON B, TORTORELLA MD: Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthritis Cartilage (1998) 6(3):214–228.
   PubMed Web of Science ®Google Scholar
• STANTON H, UNG L, FOSANG AJ: The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. Biochem. J (2002) 364(Pt 1):181–190.
   PubMedGoogle Scholar
• TORTORELLA MD, MALFAIT AM, DECCICO C, ARNER E: The role of ADAM-T54 (aggrecanase-1) and ADAM-T55 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage (2001) 9(6):539–552.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that ADAMTS-4 but notADAMTS-5 is inducible by IL-1 or TNF-a, and that ADAMTS-4 is the predominant aggrecanase in an IL-1-dependent model of cartilage destruction.
   Google Scholar
• MALFAIT AM, LIU RQ, IJIRI K, KOMIYA S, TORTORELLA MD: Inhibition of ADAM-T54 and ADAM-T55 prevents aggrecan degradation in osteoarthritic cartilage. J. Biol. Chem. (2002) 277(25):22201–22208.
   PubMed Web of Science ®Google Scholar
• YAMANISHI Y, BOYLE DL, CLARK M et al.: Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J ImmunoL (2002) 168(3):1405–1412.
   PubMed Web of Science ®Google Scholar
• VANKEMMELBEKE MN, HOLEN I, WILSON AG et al.: Expression and activity of ADAM-T55 in synovium. Eur. Biochem. (2001) 268(5):1259–1268.
   PubMedGoogle Scholar
• KOSHY PJ, LUNDY CJ, ROWAN AD et al: The modulation of matrix metalloproteinases and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum. (2002) 46(4):961–967.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO K, TAKAHASHI M, YAMAMOTO Y, SHIMADA K, TANZAWA K: Identification of aggrecanase activity in medium of cartilage culture. J Biochem. (1999) 126(2):449–455.
   PubMed Web of Science ®Google Scholar
• TORTORELLA MD, PRATTA M, LIU RQ et al: Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J. Biol. Chem. (2000) 275(24):18566–18573.
   PubMed Web of Science ®Google Scholar
• •Identifies multiple cleavage sites in aggrecan recognised by ADAMTS-4.
   Google Scholar
• MATTHEWS RT, GARY SC, ZERILLO C, PRATTA M et al.: Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. Biol. Chem. (2000) 275(30):22695–22703.
   Web of Science ®Google Scholar
• SANDY JD, WESTLING J, KENAGY RD et al: Versican V1 proteolysis in human aorta in vivo occurs at the G1u441-A1a442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J. Biol. Chem. (2001) 276:13372–13378.
   PubMed Web of Science ®Google Scholar
• PRATTA MA, TORTORELLA MD, ARNER E: Age-related changes in aggrecan glycosylation affect cleavage by aggrecanase. J. Biol. Chem. (2000) 275(50):39096–39102.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that the GAG content of aggrecan has a significant effect upon cleavage by aggrecanases.
   Google Scholar
• TORTORELLA M, PRATTA M, LIU RQ et al.: The thrombospondin motif of aggrecanase-1 (ADAM-T54) is critical for aggrecan substrate recognition and cleavage. J Biol. Chem. (2000) 275(33):25791–25797.
   PubMed Web of Science ®Google Scholar
• •Defines mechanism by which ADAMTS-4 recognises substrate.
   Google Scholar
• BREW K, DINAKARPANDIAN D, NAGASE H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta (2000) 1477:267–283.
   PubMed Web of Science ®Google Scholar
• JIANG Y, GOLDBERG ID, SHI YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene (2002) 21:2245–2252.
   PubMed Web of Science ®Google Scholar
• •Good review of more subtle roles for TWIN.
   Google Scholar
• WILLIAMSON RA, SMITH BJ, ANGAL S, MURPHY G, FREEDMAN RB: Structural analysis of tissue inhibitor of metalloproteinases-1 (TIMP-1) by tryptic peptide mapping. Biochim. Biophys. Acta (1993) 1164:8–16.
   PubMedGoogle Scholar
• MURPHY G, HOUBRECHTS A, COCKETT MI, WILLIAMSON RA, O'SHEA M, DOCHERTY AJP: The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry (1991) 30:8097–8102.
   PubMed Web of Science ®Google Scholar
• KNAUPER V, MURPHY G: Membrane-type matrix metalloproteinases and cell surface-associated activation cascades for matrix metalloproteinases. In: Matrix metalloproteinases. Parks WC, Mecham RP (Eds), Academic Press, San Diego, USA (1998):199–218.
   Google Scholar
• LECO KJ, KHOKHA R, PAVLOFF N, HAWKES SP, EDWARDS DR: Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J. Biol. Chem. (1994) 269:9352–9360.
   PubMed Web of Science ®Google Scholar
• AMOUR A, SLOCOMBE PM, WEBSTER A et al.: TNF-a converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. (1998) 435:39–44.
   PubMed Web of Science ®Google Scholar
• KASHIWAGI M, TORTORELLA M, NAGASE H, BREW K: TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-T54) and aggrecanase 2 (ADAM-T55). .j Biol. Chem. (2001) 276(16):12501–12504.
   PubMed Web of Science ®Google Scholar
• ELLIS AJ, CURRY VA, POWELL EK, CAWSTON TE: The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem. Biophys. Res. Commun. (1994) 201:94–101.
   PubMed Web of Science ®Google Scholar
• GENDRON CM, KASHIWAGI M, HUGHES CE, CATERSONB, NAGASE H: TIMP-3 inhibits aggrecanase-mediated GAG release in IL-la-stimulated bovine nasal cartilage explants. Federation of European Connective Societies (2002). Abstract P136.
   Google Scholar
• MENGSHOL JA, MIX KS, BRINCKERHOFF CE: Matrix metalloproteinases as therapeutic targets in arthritic diseases. Arthritic Rheum. (2002) 46:13–20.
   PubMed Web of Science ®Google Scholar
• BECKETT RP, WHITTAKER M: Matrix metalloproteinase inhibitors 1998. Expert. Opin.Ther. Patents (1998) 8:259–282.
   Web of Science ®Google Scholar
• MOORE WM, SPILBURG CA: Purification of human collagenases with a hydroxamic acid affinity column. Biochemistry (1986) 25:5189–5195.
   PubMed Web of Science ®Google Scholar
• BODE W, MASKOS K: Structural studies on MMPs and TIMPs. In: Matrix metalloproteinase protocols. Clark IM (Ed.), Humana Press, New Jersey, USA (2001)45–77.
   Google Scholar
• HENROTIN Y, SANCHEZ C, REGINSTER J-Y: The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives. Expert Opin. Thar. Patents (2002) 12:29–43.
   Web of Science ®Google Scholar
• WHITTAKER M, FLOYD CD, BROWN P, GEARING AJH: Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. (1999) 99:2735–2776.
   PubMed Web of Science ®Google Scholar
• BOTTOMLEY KM, JOHNSON WH, WALTER DS: Matrix metalloproteinase inhibitors in arthritis. I Enzym. Inhib. (1998) 13:79–101.
   PubMed Web of Science ®Google Scholar
• BROWN PD: Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin. Investig. Drugs (2000) 9:2167–2177.
   PubMed Web of Science ®Google Scholar
• •Good review of drug trials with IVEVIP inhibitors.
   Google Scholar
• WOJTOWICZ-PRAGA S, TORRI J, JOHNSON M et al.: Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. Clin. Oncol. (1998) 16:2150–2156.
   Web of Science ®Google Scholar
• DRUMMOND AH, BECKETT P, BROWN PD et al.: Preclinical and clinical studies of MMP inhibitors in cancer. Ann. NY Acad. Sci. (1999) 878:228–235.
   PubMed Web of Science ®Google Scholar
• BIRD J, MONTANA JG, WILLS RE, BAXTER AD, OWEN DA: Selective matrix metalloproteinase (MMP) inhibitors having reduced side-effects. Chemical Abstracts (1999) 129:225751.
   Google Scholar
• LEWIS EJ, BISHOP J, BOTTOMLEY KMK et al: Ro-32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown M vitro and M vivo. Br. Pharmacol. (1997) 121:540–546.
   PubMed Web of Science ®Google Scholar
• Roche puts arthritis drug on hold. Scrip (2000) 2528:20.
   Google Scholar
• CHAU T, JOLLY G, PLYM MJ et al: Inhibition of articular cartilage degradation in dog and guinea-pig models of osteoarthritis by the stromelysin inhibitor, BAY-12-9566. Arthritis Rheum. (1998) 41:S300.
   Google Scholar
• HAMADA T, ARIMA N, SHINDO M, SUGAMA K, SASAGURI Y: Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase inhibitor. Br..! Pharmacol. (2000) 131:1513–1520.
   PubMed Web of Science ®Google Scholar
• LEFF RL: Clinical trials of a stromelysin inhibitor. Ann. NY Acad. Sri. (1999) 878:201–207.
   PubMed Web of Science ®Google Scholar
• Bayer drug casts shadow over MMP inhibitors in cancer. Scrip (1999) 2476:7.
   Google Scholar
• MACPHERSON LJ, BAYBURT EK, CAPPARELLI MP et al.: Discovery of CGS-27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. (1997) 40:2525–2532.
   PubMed Web of Science ®Google Scholar
• O'BYRNE EM, BLANCUZZI V, SINGH H, MACPHERSON LJ, PARKER DT, ROBERTS ED: Chondroprotective activity of a matrix metalloproteinase inhibitor, CGS 27023A in animal models of osteoarthritis. In: Advances in Osteoarthritis Tanaka S, Hamanishi C (Eds), Springer-Verlag, Tokyo, Japan (1999):163–173.
   Google Scholar
• LEVITT NC, ESKENS F, O'BYRNE KJ et al.: Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor MM1270 (CGS-27023A), in patients with advanced solid cancer. Clin. Cancer Res. (2001) 7:1912–1922.
   Google Scholar
• BANK RA, TEKOPPELE JM, OOSTINGH G, HAZLEMAN BL, RILEY GP: Lysylhydroxylation and non-reducible crosslinking of human supraspinatus tendon collagen: changes with age and in chronic rotator cuff tendonitis. Ann. Rheum. Dis. (1999) 58:35–41.
   PubMed Web of Science ®Google Scholar
• RILEY GP, CURRY V, DEGROOT Jet al.: Matrix metalloproteinase activities and their relationship with collagen remodelling in tendon pathology. Matrix Biol. (2002) 21:185–195.
   Google Scholar
• •Paper highlighting the role of MMPs in tendon metabolism, relevant to MMP inhibitor-induced tendinitis.
   Google Scholar
• IRELAND D, HARRALL R, CURRY V et al.: Multiple changes in gene expression in chronic human Achilles tendinopathy. Matrix Biol. (2001) 20:159–169.
   PubMed Web of Science ®Google Scholar
• BAYLISS MT, HUTTON S, HAYVVARD J, MACIEWICZ RA: Distribution of aggrecanase (ADAMts 4/5) cleavage products in normal and osteoarthritic human articular cartilage: the influence of age, topography and zone of tissue. Osteoarthritis Cartilage (2001) 9(6):553–560. los. LOHMANDER S, HOERRNER LA, LARK MW: Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritic Rheum. (1993) 36(2):181–189.
   Google Scholar
• DODGE GR, POOLE AR: Immunohistochemical detection and immunochemical analysis of Type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. Clin. Invest. (1989) 83:647–661.
   Google Scholar
• WU W, BILLINGHURST RC, PIDOUX I et al.: Sites of collagenase cleavage and denaturation of Type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum. (2002) 46:2087–2094.
   PubMed Web of Science ®Google Scholar
• •Parallel staining for collagen cleavage neoepitopes and collagenases in normal and OA cartilage. los. FELDMANN M, MAINI RN: Discovery of TNF-a as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine (2002) 69:12–18.
   Google Scholar
• CATRINA Al, LAMPA J, ERNESTAM S et al: Anti-tumour necrosis factor (TNE)-a therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (2002) 41:484–489.
   PubMed Web of Science ®Google Scholar
• MASKOS K, FERNANDEZ-CATALAN C, HUNER R et al.: Crystal structure of the catalytic domain of human tumour necrosis factor-alpha-converting enzyme. Proc. Nati Acad. Sri. USA (1998) 95(7):3408–3412.
   PubMed Web of Science ®Google Scholar
• NEWTON RC, SOLOMON KA, COVINGTON MB et al: Biology of TACE inhibition. Ann. Rheum. Dis. (2002) 60\(Suppl. 3):25–32.
   Google Scholar
• YAO W, WASSERMAN ZR, CHAO M et al.: Design and synthesis of a series of (2R)-N(4)-hydroxy 2 (3 hydrobenzy1)-N(1)-[(1S,2R)-2-hydroxy-2,3-dihydro-lH-inden-1-yl] butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. I Med. Chem. (2001) 44(21):3347–3350.
   PubMed Web of Science ®Google Scholar
• YAO W, CHAO M, WASSERMAN ZR et al.: Potent P1 biphenylmethyl substituted
   Google Scholar
• •• aggrecanase inhibitors. Bioorg. Med. Chem. Letts. (2002) 12:101–104.
   Google Scholar
• HOLMS J, MAST K, MARCOTTE P et al.: Discovery of selective hydroxamic acid inhibitors of tumour necrosis factor-a converting enzyme. Bioorg. Med. Chem. Lett. (2001) 11:2907–2910
   PubMed Web of Science ®Google Scholar
• CONWAY JG, ANDREWS RC, BEAUDET B et al: Inhibition of tumour necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW-3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases. Pharmacol Exp. Titer: (2001) 298(3):900–908.
   PubMed Web of Science ®Google Scholar
• HOOPER NM, TURNER AJ: The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer's disease. Curr. Med. Chem. (2002) 9:1107–1119.
   PubMed Web of Science ®Google Scholar
• VAN EERDEWEGH P, LITTLE RD, DUPUIS J et al.: Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature (2002) 418:426–430.
   PubMed Web of Science ®Google Scholar
• ZHENG X, CHUNG D, TAKAYAMA TK, MAJERUS EM, SADLER JE, FUJIKAWA K: Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J. Biol. Chem. (2001) 276(44):41059–41063.
   PubMed Web of Science ®Google Scholar
• LEVY GG, NICHOLS WC, LIAN EC et al: Mutations in a member of the ADAMTS gene family causes thrombotic thrombocytopenic purpura. Nature (2001) 413:488–494.
   PubMed Web of Science ®Google Scholar
• LI S-W, ARITA M, FERTALA A et al: Transgenic mice with inactive alleles for procollagen N-proteinase (ADAM-T52) develop fragile skin and male sterility. Biochem. (2001) 355:271–278.
   Google Scholar
• COLIGE A, VANDENBERGHE I, THIRY M et al.: Cloning and characterisation of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3. I Biol Chem. (2002) 277:5756–5766.
   Web of Science ®Google Scholar
• FERNANDES RJ, HIROHATA S, ENGLE JM et al.: Procollagen II amino propeptide processing by ADAM-T53. Biol. Chem. (2001) 276(34):31502–31509.
   Web of Science ®Google Scholar
• ASHLEY RA: Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. Ann. NY Acad. Sci. (1999) 878:335–346.
   PubMed Web of Science ®Google Scholar
• ALARCON GS: Tetracyclines for the treatment of rheumatoid arthritis. Expert Opin. Investig. Drugs (2000) 9:1491–1498.
   PubMed Web of Science ®Google Scholar
• O'DELL JR, BLAKELY KW, MALLEK JA et al: Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum. (2001) 44:2235–2241.
   PubMedGoogle Scholar
• VAN DER LAAN W, MOLENAAR E, RONDAY K et al.: Lack of effect of doxycycline on disease activity and joint damage in patients with rheumatoid arthritis. A double blind, placebo controlled trial. Rheumatol. (2001) 28:1967–1974.
   Google Scholar
• VINCENTI MP, BRINCKERHOFF CE: Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signalling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. (2002) 4:157–164.
   PubMedGoogle Scholar
• •Review of signalling pathways in regulation of MMP gene expression.
   Google Scholar
• DOUGADOS M, NGUYEN M, BERDAH L, MAZIERES B, VIGNON E, LEQUESNE M: Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis. Arthritis Rheum. (2001) 44:2539–2547.
   PubMed Web of Science ®Google Scholar
• MIX KS, MENGSHOL JA, BENBOW U, VINCENTI MP, SPORN MB, BRINCKERHOFF CE: A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum. (2001) 44:1096–1104.
   PubMed Web of Science ®Google Scholar
• CURTIS CL, REES SG, LITTLE CB et al: Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids. Arthritis Rheum. (2002) 46:1544–1553.
   PubMed Web of Science ®Google Scholar
• APPARAILLY F, NOEL D, MILLET V et al.: Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. Arthritis Rheum. (2001) 44:1444–1454.
   PubMed Web of Science ®Google Scholar
• SCHETT G, HAYER S, TOHIDAST-AKRAD M et al.: Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumour necrosis factor a transgenic mice. Arthritis Rheum. (2001) 44:2888–2898.
   PubMed Web of Science ®Google Scholar
• EVANS CH, GHIVIZZANI SC, PALMERGD, GOUZE JN, ROBBINS PD, GOUZE E: Gene therapy for rheumatoid arthritis. Expert Opin. Biol. Ther. (2001) 1:971–978.
   PubMed Web of Science ®Google Scholar
• VAN DE LOO FA, VAN DEN BERG WB: Gene therapy for rheumatoid arthritis. Rheum. Dis. Clin. North Am. (2002) 28:127–149.
   PubMed Web of Science ®Google Scholar
• DOHERTY TM, ASOTRA K, PEI D et al: Therpeutic developments in matrix metalloproteinase inhibition. Expert Opin. Ther: Patents (2002) 12:665–707.
   Web of Science ®Google Scholar
• ••Excellent review of WIMP inhibitors in avariety of pathologies.
   Google Scholar
• PATTERSON ML, ATKINSON SJ, KNAUPER K, MURPHY G: Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett. (2001) 17:158–162.
   Google Scholar
• GOLDRING SR: Bone and joint destruction in rheumatoid arthritis: what is really happening?' Rheumatol. (2002) 65:44–48.
   Google Scholar
• HOU WS, LI W, KEYSZER et al: Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. (2002) 46:663–674.
   PubMed Web of Science ®Google Scholar
• MCCAULEY TR, RECHT MP, DISLER DG: Clinical imaging of articular cartilage in the knee. Semin. Muscuoskelet. Radiol (2001) 5:293–304.
   PubMedGoogle Scholar
• GOLD GE, BEAULIEU CF: Future of MR imaging of articular cartilage. Semin. Muscuoskelet. Radial. (2001) 5:313–327.
   PubMedGoogle Scholar